An Open Label, Single Centre, Phase I Study of PI3K Inhibitor BAY80-6946 to Evaluate the Safety, Tolerability and Pharmacokinetics in Japanese Patients With Advanced or Refractory Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Copanlisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 23 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 23 Jul 2012 Actual patient number changed from 9 to 10 as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.